Acute effects of digoxin on plasma aldosterone and cortisol in monkeys

Metabolism: Clinical and Experimental

Volumn 58, Issue 1, 2009, Pages 55-61

  Kau, Mei Mei ^a   Kan, Shu Fen ^b   Wang, Jiing Rong ^b   Wang, Paulus S ^b   Lau, Ying Tung ^c   Wang, Shyi Wu ^c  

^a NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDOSTERONE; CORTICOTROPIN; DIGOXIN; HYDROCORTISONE; OUABAIN; POTASSIUM; POTASSIUM CHLORIDE; SODIUM;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HYDROCORTISONE BLOOD LEVEL; MALE; MONKEY; NONHUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; STEROID RELEASE;

ALDOSTERONE; ANIMALS; CARDIOTONIC AGENTS; DIGOXIN; FEMALE; HYDROCORTISONE; MACACA; MALE; OUABAIN; POTASSIUM; SODIUM; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 57049189191     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.08.006     Document Type: Article

References (48)

1. Iisalo E. Clinical pharmacokinetics of digoxin. Clin Pharmacokinet 2 (1977) 1-16
2. Hougen T.J., and Smith T.W. Inhibition of myocardial monovalent cation active transport by subtoxic doses of ouabain in the dog. Circ Res 42 (1978) 856-863
3. +-ATPase. J Biol Chem 269 (1994) 19659-19662
4. Antonipillai I., Schick K., and Horton R. Ouabain is a potent inhibitor of aldosterone secretion and angiotensin action in the human adrenal. J Clin Endocrinol Metab 81 (1996) 2335-2337
5. Hansen O. No evidence for a role in signal-transduction of Na+/K+-ATPase interaction with putative endogenous ouabain. Eur J Biochem 270 (2003) 1916-1919
6. Sweadner K.J. Isozymes of the Na+/K+-ATPase. Biochim Biophys Acta 988 (1989) 185-220
7. Lin H., Wang S.W., Tsai S.C., Chen J.J., Chiao Y.C., Lu C.C., et al. Inhibitory effect of digoxin on testosterone secretion through mechanisms involving decreases of cyclic AMP production and cytochrome P450scc activity in rat testicular interstitial cells. Br J Pharmacol 125 (1998) 1635-1640
8. Wang S.W., Lin H., Hwang J.J., and Wang P.S. Inhibition of testosterone secretion by digoxin in rat testicular interstitial cells. J Cell Biochem 74 (1999) 74-80
9. Chen J.J., Chien E.J., and Wang P.S. Progesterone attenuates the inhibitory effects of cardiotonic digitalis on pregnenolone production in rat luteal cells. J Cell Biochem 86 (2002) 107-117
10. Chen J.J., Wang P.S., Chien E.J., and Wang S.W. Direct inhibitory effect of digitalis on progesterone release from rat granulosa cells. Br J Pharmacol 132 (2001) 1761-1768
11. Wang S.W., Pu H.F., Kan S.F., Tseng C.I., Lo M.J., and Wang S.W. Inhibitory effects of digoxin and digitoxin on corticosterone production in rat zona fasciculata-reticularis cells. Br J Pharmacol 142 (2004) 1123-1130
12. Hamlyn J.M., Blaustein M.P., Bova S., DuCharme D.W., Harris D.W., Mandel F., et al. Identification and characterization of an ouabain-like compound from human plasma. Proc Natl Acad Sci U S A 88 (1991) 6259-6263
13. De Angelis C., Riscazzi M., Salvini R., Piccoli A., Ferri C., and Santucci A. Isolation and characterization of a digoxin-like immunoreactive substance from human urine by affinity chromatography. Clin Chem 43 (1997) 1416-1420
14. Ludens J.H., Clark M.A., Robinson F.G., and DuCharme D.W. Rat adrenal cortex is a source of a circulating ouabainlike compound. Hypertension 19 (1992) 721-724
15. Li S., Eim C., Kirch U., Lang R.E., and Schoner W. Bovine adrenals and hypothalamus are a major source of proscillaridin A- and ouabain-immunoreactivities. Life Sci 62 (1998) 1023-1033
16. Tymiak A.A., Norman J.A., Bolgar M., DiDonato G.C., Lee H., Parker W.L., et al. Physicochemical characterization of an ouabain isomer isolated from bovine hypothalamus. Proc Natl Acad Sci U S A 90 (1993) 8189-8193
17. Doris P.A., Hayward-Lester A., Bourne D., and Stocco D.M. Ouabain production by cultured adrenal cells. Endocrinology 137 (1996) 533-539
18. Laredo J., Hamilton B.P., and Hamlyn J.M. Ouabain is secreted by bovine adrenocortical cells. Endocrinology 135 (1994) 794-797
19. Graves S.W., Brown B., and Valdes Jr. R. An endogenous digoxin-like substance in patients with renal impairment. Ann Intern Med 99 (1983) 604-608
20. Rossi G., Manunta P., Hamlyn J.M., Pavan E., De Toni R., Semplicini A., et al. Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels. J Hypertens 13 (1995) 1181-1191
21. Valdes Jr. R., and Graves S.W. Protein binding of endogenous digoxin-immunoactive factors in human serum and its variation with clinical condition. J Clin Endocrinol Metab 60 (1985) 1135-1143
22. Doris P.A., and Bagrov A.Y. Endogenous sodium pump inhibitors and blood pressure regulation: an update on recent progress. Proc Soc Exp Biol Med 218 (1998) 156-167
23. Hollenberg N.K., and Graves S.W. Endogenous sodium pump inhibition: current status and therapeutic opportunities. Prog Drug Res 46 (1996) 9-42
24. Braley L.M., and Williams G.H. The effects of ouabain on steroid production by rat adrenal cells stimulated by angiotensin II, alpha 1-24 adrenocorticotropin, and potassium. Endocrinology 103 (1978) 1997-2005
25. Covit A.B., Schaer G.L., Sealey J.E., Laragh J.H., and Cody R.J. Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure. Am J Med 75 (1983) 445-447
26. Guthrie Jr. G.P. Effects of digoxin on responsiveness to the pressure actions of angiotensin and norepinephrine in man. J Clin Endocrinol Metab 58 (1984) 76-80
27. + pump in rat adrenal glomerulosa cells: possible contribution to stimulation of aldosterone production. Endocrinology 130 (1992) 1637-1644
28. Neri G., De Toni R., Tortorella C., Rebuffat P., Bova S., Cargnelli G., et al. Ouabain chronic infusion enhances the growth and steroidogenic capacity of rat adrenal zona glomerulosa: the possible involvement of the endothelin system. Int J Mol Med 18 (2006) 315-319
29. Pistorello M., Cimolato M., Pedini F., Piovan D., Boscaro M., and Fallo F. Effect of digoxin on the in vitro secretion of renin and angiotensin II/III immunoreactivity by the human adrenal gland. Acta Endocrinol 127 (1992) 210-214
30. Kau M.M., Kan S.F., Wang J.R., and Wang P.S. Inhibitory effects of digoxin and ouabain on aldosterone synthesis in human adrenocortical NCI-H295 cells. J Cell Physiol 205 (2005) 393-401
31. Kau M.M., Chang L.L., Kan S.F., Ho L.T., and Wang P.S. Stimulatory effects of hyperprolactinemia on aldosterone secretion in ovariectomized rats. J Investig Med 50 (2002) 101-109
32. Steel R.G.D., and Torrie J.H. Principles and procedures of statistics (1960), McGraw-Hill, New York
33. Elliott M.E., Hadjokas N.E., and Goodfriend T.L. Effects of ouabain and potassium on protein synthesis and angiotensin-stimulated aldosterone synthesis in bovine adrenal glomerulosa cells. Endocrinology 118 (1986) 1469-1475
34. Clark W.G., Brater D.C., and Johnson A.R. Digitalis. Goth's medical pharmacology (1992), Mosby Year Book, St. Louis, (Mo)
35. Valdes Jr. R., Jortani S.A., and Gheorghiade M. Standards of laboratory practice: cardiac drug monitoring. Clin Chem 44 (1998) 1096-1109
36. Struthers A.D., Davies D.L., Harland D., Price J.S., Brown R.A., Quigley C., et al. Adrenaline causes potassium influx in skeletal muscle and potassium efflux in cardiac muscle in rats: the role of Na/K ATPase. Life Sci 40 (1987) 101-108
37. El-Masri M.A., Clark B.J., Qazzaz H.M., and Valdes Jr. R. Human adrenal cells in culture produce both ouabain-like and dihydroouabain-like factors. Clin Chem 48 (2002) 1720-1730
38. Laredo J., Shah J.R., Lu Z.R., Hamilton B.P., and Hamlyn J.M. Angiotensin II stimulates secretion of endogenous ouabain from bovine adrenocortical cells via angiotensin type 2 receptors. Hypertension 29 (1997) 401-407
39. Shah J.R., Laredo J., Hamilton B.P., and Hamlyn J.M. Different signaling pathways mediate stimulated secretions of endogenous ouabain and aldosterone from bovine adrenocortical cells. Hypertension 31 (1998) 463-468
40. Shah J.R., Laredo J., Hamilton B.P., and Hamlyn J.M. Effects of angiotensin II on sodium potassium pumps, endogenous ouabain, and aldosterone in bovine zona glomerulosa cells. Hypertension 33 (1999) 373-377
41. Barr C.S., Lang C.C., Hanson J., Arnott M., Kennedy N., and Struthers A.D. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 76 (1995) 1259-1265
42. Swedberg K., Eneroth P., Kjekshus J., and Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 82 (1990) 1730-1736
43. Brilla C.G., Pick R., Tan L.B., Janicki J.S., and Weber K.T. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67 (1990) 1355-1364
44. Weber K.T., and Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83 (1991) 1849-1865
45. Rocha R., Chander P.N., Khanna K., Zuckerman A., and Stier Jr. C.T. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31 (1998) 451-458
46. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
47. Brilla C.G., Matsubara L.S., and Weber K.T. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 25 (1993) 563-575
48. MacFadyen R.J., Barr C.S., and Struthers A.D. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 35 (1997) 30-34